The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! About 4.24M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 52.92% since April 22, 2016 and is downtrending. It has underperformed by 58.33% the S&P500.
The move comes after 7 months positive chart setup for the $5.75 billion company. It was reported on Nov, 25 by Barchart.com. We have $18.11 PT which if reached, will make NYSE:VRX worth $287.50M more.
Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on March, 21. They expect $1.34 EPS, down 46.61% or $1.17 from last year’s $2.51 per share. VRX’s profit will be $447.18 million for 3.22 P/E if the $1.34 EPS becomes a reality. After $1.55 actual EPS reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -13.55% negative EPS growth.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 3 “Sell”, while 12 “Hold”. This means 35% are positive. Valeant Pharmaceuticals Intl has been the topic of 80 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, November 3. The stock has “Buy” rating given by UBS on Friday, October 30. On Thursday, November 10 the stock rating was downgraded by Rodman & Renshaw to “Neutral”. On Wednesday, March 16 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm earned “Overweight” rating on Wednesday, March 16 by JP Morgan. The firm earned “Buy” rating on Tuesday, July 21 by BTIG Research. The firm has “Hold” rating given on Friday, October 14 by Deutsche Bank. The company was downgraded on Monday, March 21 by Barclays Capital. Scotia Capital maintained the stock with “Sector Outperform” rating in Friday, July 24 report. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Hold” rating by Deutsche Bank on Tuesday, September 20.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Invesco holds 71,293 shares or 0% of its portfolio. Kcg has 0.04% invested in the company for 97,627 shares. Duncker Streett owns 200 shares or 0% of their US portfolio. The South Africa-based Old Mutual Customised Solutions (Proprietary) has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). International Group Incorporated holds 0% or 4,200 shares in its portfolio. Nexus Invest reported 22,910 shares or 0.09% of all its holdings. First Western Cap Mngmt last reported 0.24% of its portfolio in the stock. Credit Suisse Ag has 972,619 shares for 0.02% of their US portfolio. Joel Isaacson & Com Ltd Liability Corporation accumulated 160 shares or 0% of the stock. Blackrock has 32,400 shares for 0% of their US portfolio. Prescott Mngmt Ltd Limited Liability Company accumulated 0.32% or 65,000 shares. Shell Asset Management Communication last reported 0.03% of its portfolio in the stock. Franklin Resource accumulated 0% or 402,925 shares. Royal Comml Bank Of Canada has invested 0.03% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Apriem Advsrs has 0.01% invested in the company for 775 shares.
Insider Transactions: Since June 9, 2016, the stock had 2 buys, and 0 selling transactions for $5.04 million net activity. $4.94 million worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was bought by PAPA JOSEPH C on Thursday, June 9. On Thursday, August 11 KARABELAS ARGERIS N bought $98,600 worth of the stock or 4,000 shares.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock” on November 24, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” on November 10, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Fool.com‘s news article titled: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” with publication date: November 01, 2016.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.